Alpha synuclein detects early Parkinson
- Trial ID
- NCT06232772
- Official Title
- Research on Novel Biomarkers for Early Diagnosis of Parkinson's Disease:An Observational, Multicenter, Non-Randomized Controlled Study
- Goal
- Alpha synuclein detects early Parkinson
- Status
- RECRUITING
- Sponsor
- Yousheng Xiao
- Study Type
- OBSERVATIONAL
- Enrollment
- 600 participants
- Conditions
- Parkinson's Disease
- Interventions
- α- Synuclein Ultrafine Fluorescence Detection Method
Plain-Language Summary
The goal is to find early, reliable markers that can diagnose Parkinson's sooner and help tell Parkinson's apart from similar conditions like MSA and PSP so people get the right care faster. Researchers are using an ultrafine fluorescence technique to detect misfolded alpha-synuclein, the protein that clumps in Parkinson's, by making those tiny aggregates light up in biological samples; because it is observational the test does not change treatments or interact with levodopa. About 600 adults aged 18 to 80 will be enrolled, including people with clinically confirmed or probable early-stage PD (Hoehn and Yahr ≤ 2.5), plus comparison groups with MSA and PSP and healthy matched controls. People with secondary Parkinsonism from drugs or vascular causes, severe cognitive impairment, or other major neurodegenerative diseases are not eligible.
Locations
- Guangxi Medical University, Nanning, Guangxi, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying α- Synuclein Ultrafine Fluorescence Detection Method. The goal is to find early, reliable markers that can diagnose Parkinson's sooner and help tell Parkinson's apart from similar conditions like MSA and PSP so people get the right care faster. Researchers are using an ultrafine fluorescence technique to detect misfolded alpha-synuclein, the protein that clumps in Parkinson's, by making those tiny aggregates light up in biological samples; because it is observational the test does not change treatments or interact with levodopa. About 600 adults aged 18 to 80 will be enrolled, including people with clinically confirmed or probable early-stage PD (Hoehn and Yahr ≤ 2.5), plus comparison groups with MSA and PSP and healthy matched controls. People with secondary Parkinsonism from drugs or vascular causes, severe cognitive impairment, or other major neurodegenerative diseases are not eligible.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 2 months.